Beta 2 adrenergic receptor agonists such as terbutaline for use in the treatment of nocturnal hypoglycemia

摘要

The invention is concerned with methods, regimens and dosage forms employing a beta 2 adrenergic receptor agonist such as terbutaline sulphate, for treating nocturnal hypoglycaemia in human subjects whilst reducing incidence of hyperglycaemia in said subjects upon wakening.